Telemark Fund LP discloses 7.3% stake in Codexis via SEC 13G filing
Telemark Fund LP reported a 7.3% stake in Codexis as of July 24, 2026, through an SEC 13G filing. This disclosure confirms the fund's status as a major shareholder, offering insight into the company's institutional investor base.
*this image is generated using AI for illustrative purposes only.
Telemark Fund LP holds a 7.3% stake in Codexis as of July 24, 2026, according to a recent Schedule 13G filing with the Securities and Exchange Commission (SEC). The disclosure highlights the fund’s significant institutional ownership in the biotechnology company, providing transparency into major shareholder positions during this reporting period.
Filing Details
The Schedule 13G filing serves as the formal mechanism for reporting beneficial ownership of more than 5% of a class of equity securities. By submitting this document, Telemark Fund LP complied with regulatory requirements to disclose its investment level to the market.
| Entity | Stake Percentage | Date of Record | Filing Type |
|---|---|---|---|
| Telemark Fund LP | 7.3% | July 24, 2026 | Schedule 13G |
Market Implications
A 7.3% stake represents a material holding, indicating that Telemark Fund LP is a key investor in Codexis. Such disclosures are critical for market participants assessing shareholder structure and potential influence on corporate governance. The timing of the filing aligns with standard reporting obligations for significant equity positions.
How might Telemark Fund LP's 7.3% stake influence Codexis's upcoming board elections or corporate governance decisions?
Does this filing signal Telemark's intent to increase its position, or is it a passive holding consistent with their broader biotech portfolio strategy?
What impact could this institutional endorsement have on Codexis's stock volatility and trading volume in the near term?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
